Lasonil Antidolore: Main Therapeutic Uses and Benefits

Lasonil Antidolore contains the active substance etofenamate and is applied across domains where additional symptomatic support is needed. It is commonly used to help with symptoms related to physical discomfort and symptoms related to inflammatory or irritative states.

The product is relevant in conditions characterized by periods of heightened symptoms. It is applied across domains where additional symptomatic support is needed, including situations involving certain distressing symptoms such as those linked to minor soft tissue injuries, or conditions involving inflammatory or irritative processes like osteoarthrosis/osteoarthritis, synovitis, bursitis, and tendinitis.

The supportive relief provided contributes to easing the overall symptom load during periods of heightened symptoms. The application is considered relevant for easing symptoms that interfere with daily comfort, and is applied in scenarios where additional management of discomfort is required. It helps address symptom clusters that may become intense or disruptive, such as muscle pain, post-traumatic discomfort, and joint pain. This supports general well-being during symptomatic phases.

Quick Fact: Relevant for Symptomatic Management of Musculoskeletal Discomfort

Regulatory References

1. HPRA Summary of Product Characteristics for Etoflam Gel

Who can and cannot use Lasonil Antidolore

Population eligibility for Lasonil Antidolore (topical Ibuprofen lysine salt) is strictly defined by regulatory authorities, establishing both absolute contraindications and conditions for restricted use.

Contraindicated Populations

Use of the medicine is contraindicated for individuals with known hypersensitivity to ibuprofen, Aspirin, or any other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). This includes patients with a history of NSAID-induced asthma, rhinitis, or urticaria. Application is also prohibited on broken, damaged, infected, or eczematous skin.

---

Age- and Reproductive-Status Eligibility

Population Group	Regulatory Status
Children (Under 14 years)	Contraindicated / Not recommended
Pregnancy (Third Trimester)	Contraindicated (Absolute Prohibition)
Lactation (Breastfeeding)	Not recommended / Contraindicated
Older Adults (Geriatric)	Use requires Caution

---

Conditional Use Restrictions

Use is subject to caution or requires medical consultation for patients with a history of active peptic ulcers or kidney problems (renal impairment). The medicine is not recommended for women during the first and second trimesters of pregnancy.

Interactions with other medicines and products

Interaction Scope

The regulatory profile for this topical preparation is primarily structured by its minimal systemic absorption, meaning that the complex systemic pharmacokinetic interactions characteristic of oral nonsteroidal anti-inflammatory drugs (NSAIDs) are not formally documented in the product labeling.

Property	Official Regulatory Information
Medicinal product categories with documented interactions:	Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including other topical and systemic Ibuprofen-containing products.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic interaction (additive effects), where regulatory sources cite the potential for increased adverse reactions from co-administration.
Timing-based interaction rules (if applicable):	None. No mandatory timing separation rules are documented for co-administration with other medicinal products.

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification:	Generally classified as a precaution against additive local or systemic adverse effects. No major systemic drug-drug interactions are documented.
Non-Medicinal Interactions:	No systemic interactions are documented with food, alcohol, or herbal products.

Official Interaction Statements

The most significant interaction-related restriction is the caution against co-administration with other NSAIDs, regardless of whether they are topical or taken orally. Due to the low systemic exposure, the regulatory documentation confirms that clinically significant interactions involving CYP enzymes, drug transporters, or subsequent alteration of drug levels are not listed in the official product labeling.

Molecular Inhibition of the COX Pathway

The core mechanism involves the reversible, competitive inhibition of both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. This action blocks the rate-limiting step of the Arachidonic Acid Cascade, thereby preventing the conversion of arachidonic acid into prostanoids. The mechanism engages key molecular targets to suppress an overactive synthesis pathway, thus initiating the modulation of the acute inflammatory cascade.

---

⬇️ Suppression of Prostaglandin Synthesis

By halting the upstream COX activity, the drug reduces the local biosynthesis of pro-inflammatory prostaglandins, particularly PGE2, at the site of application. This pathway suppression contributes to the resulting physiological changes by reducing the concentration of potent signaling molecules in peripheral tissues. This targeted chemical blockade is the basis for the subsequent local physiological adjustments.

---

Anti-Nociception and Vascular Modulation

The reduced concentration of PGE2 diminishes the chemical sensitization of peripheral nociceptors (pain-sensing nerve endings). Concurrently, this suppression restricts prostaglandin-mediated vasodilation and increased microvascular permeability, which results in a restriction of localized fluid extravasation. These mechanistic cascades result in predictable physiological adjustments, contributing to altered signaling dynamics within both the nociceptive and local inflammatory pathways.

Administration Scope and Official Dosing

Lasonil Antidolore is an Ibuprofen-based topical medicine administered via cutaneous application to the skin. The product is typically formulated as a gel, and the dosing schedule is defined by both the frequency of application and the maximum total amount applied daily. The standard single dose consists of applying a measured strip of gel, generally between 2 cm to 10 cm in length, to the affected localized area.

The preparation may be applied up to 4 times daily, but with a requirement to maintain a minimum interval of at least 4 hours between consecutive applications. The total cumulative dose in any 24-hour period must not exceed the maximum daily amount, which corresponds to approximately 375 mg to 500 mg of Ibuprofen, depending on the specific product strength.

Procedural Structure and Use Constraints

The usage protocol is designated for short-term use. If the condition does not resolve or symptoms persist after 2 weeks of continuous use, medical review is required. The measured gel is lightly and gently rubbed into the skin until it is fully absorbed. Hands are typically washed immediately after the application is complete, unless the hands are the area being treated.

Usage instructions also specify high-level constraints: the medicine is for external use only and is generally not recommended for use in individuals under 12 years of age. Furthermore, the topical application should avoid contact with mucous membranes, eyes, or damaged skin, and it must not be used under occlusive (non-porous) dressings.

Lasonil Antidolore: Recent Clinical Evidence

Early-Stage Research: Mechanism Exploration

Research has explored whether the compound acts by enhancing the activity of specific receptors in the central nervous system. These non-human studies primarily focused on characterizing the absorption, distribution, metabolism, and excretion (ADME) profile of the compound. The initial goal was to investigate if there is a sustained reduction in symptoms when the compound is administered in animal models. Findings informed the design of Phase I human trials, primarily to assess preliminary safety and tolerability.

---

Clinical Trials (Phase I-III) Overview

Phase II Findings: Combination Therapy

Phase II trials examined the effects of the compound when used in combination with an existing standard-of-care medication. These studies evaluated whether the combination was associated with improved patient comfort and a reduction in pain scores.

• Dosage: The trials explored a range of dosages to identify a dose with an acceptable balance of participant-reported side effects and potential symptom changes.
• Duration: Most Phase II studies were conducted over a period of 4 to 8 weeks.
• Reported Outcomes: Trials have examined whether participants report an overall change in daily symptom severity compared to a placebo group.

Comparative Research

Phase III studies compared the new combination to older treatments. One study found that participants receiving the new combination reported a change in symptom severity earlier than participants in the older treatment group, though overall long-term outcomes were similar.

Research has explored whether this approach is associated with positive outcomes for patients with mild to moderate forms of the condition. Evidence remains limited regarding the use of the compound in participants experiencing long-term chronic symptoms. Studies on severe conditions are limited, and this group was excluded from several trials.

Key Studies & References

1. Drug combinations in pain treatment: a review of the published evidence and a method for finding the optimal combination
2. Lasonil Antidolore 10% Ibuprofen Gel Product Information/Monograph (as used to determine indications, contraindications, and general safety profile)

Common questions about Lasonil Antidolore (FAQ)

Q: What types of pain is Lasonil Antidolore primarily intended to treat?

Regulatory documents state that this gel is indicated for the local treatment of painful conditions.

This includes discomfort associated with muscle strains, myalgia, tendinitis, contractures, lumbago, stiff neck, sprains, and bruises.

Q: Can Lasonil Antidolore be used for pain relief in cases of bruises or sprains?

According to the official product information, both sprains and bruises are explicitly listed among the conditions the gel is indicated to treat for local pain relief. The product is designed to provide topical, localized relief.

Q: What is the expected duration of pain relief from one application of Lasonil Antidolore?

The official documentation does not specify a precise duration for pain relief. However, the regulatory use constraints state that a minimum interval of at least 4 hours must be maintained between consecutive applications of the gel.

Q: Is it possible to use Lasonil Antidolore for chronic joint pain?

The preparation is designated for short-term symptomatic use to address localized pain. Regulatory guidance states that if symptoms do not resolve or persist after 2 weeks of continuous use, medical consultation is required to assess the condition.

Q: What are the signs of a hypersensitivity or allergic reaction to Lasonil Antidolore?

Official documentation warns of the potential for generalized hypersensitivity reactions, which may include swelling beneath the skin (angioedema) or difficulty breathing (bronchospasm). The product is strictly contraindicated for anyone with a known history of NSAID-induced allergic reactions.

Q: Can Lasonil Antidolore Gel interact with oral pain relievers?

Regulatory documents advise caution against using this gel with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), regardless of whether they are topical or taken orally. This caution is due to the potential for additive effects that could increase the risk of adverse reactions.

Q: Is Lasonil Antidolore Gel absorbed into the bloodstream?

According to the product’s regulatory profile, the gel is characterized by minimal systemic absorption. This means that only a very low level of the active substance reaches the general bloodstream, distinguishing it from oral medications.

Q: Does using Lasonil Antidolore for a long time increase the risk of side effects?

The product is indicated for short-term use. Regulatory sources indicate that the product should be used at the lowest effective dose for the shortest possible duration. Warnings also include a theoretical risk of interaction with blood thinners if the gel is used over large skin areas for a prolonged period.

Q: How does a topical NSAID like Lasonil Antidolore differ from an oral NSAID in terms of body effects?

Due to its minimal systemic absorption, the topical gel's adverse reactions are primarily limited to the application site. Regulatory documents note that the complex systemic pharmacokinetic interactions typical of oral NSAIDs are not formally documented for the gel.

Q: What is the purpose of the excipients in the Lasonil Antidolore Gel formula?

Excipients are the non-active ingredients in the product. Their purpose is generally structural and functional, such as to stabilize the formulation, provide the gel consistency, or aid the active ingredient in spreading across the skin.

Q: Is Lasonil Antidolore effective for relieving pain from arthritis?

Official indications list local treatment of joint pain. However, the clinical evidence overview states that studies and evidence remain limited regarding the use of the compound in participants experiencing long-term chronic symptoms.

Q: Can people with kidney or liver issues use Lasonil Antidolore Gel?

The regulatory document advises caution and requires medical consultation for patients with a history of kidney problems (renal impairment). The official product information does not specify conditional use for liver (hepatic) issues for the topical formulation.

Q: Are there any common misuses of Lasonil Antidolore that I should be aware of?

Official documents contain several prohibitions that prevent misuse. These include avoiding use under occlusive dressings (non-porous wraps), not applying the gel to broken or damaged skin, and not using it beyond two weeks without medical consultation. The product is also not recommended for children under 14 years old.

Q: Do studies support the use of Lasonil Antidolore for conditions like tendinitis or lumbago?

Yes, official regulatory documents explicitly list tendinitis and lumbago (lower back pain) among the conditions the gel is indicated to treat for local pain relief.

Q: Are there different versions or concentrations of Lasonil Antidolore available?

Regulatory information describes Lasonil Antidolore Gel as containing 10% Ibuprofen lysine salt. The official documents do not describe other concentrations or different topical versions of the product.

Q: Is the lavender essence included in the gel for a specific purpose?

The official excipient lists confirm the presence of lavender essence. In such medicinal formulations, this substance is typically included to provide a fragrance.

Q: Does Lasonil Antidolore contain parabens?

Yes, the official list of excipients confirms the inclusion of substances like sodium methyl parahydroxybenzoate and sodium ethyl parahydroxybenzoate, which are forms of parabens used as preservatives.

Q: Why is the drug described as an 'antirheumatic' in some descriptions?

Official regulatory descriptions classify the product as an anti-inflammatory and antirheumatic gel. This classification is consistent with its indicated use for painful conditions affecting soft tissues like muscles, tendons, and joints.

Q: Does Lasonil Antidolore have any sedative properties?

The official side effect profile focuses on local effects and does not list drowsiness or sedation as a known or common reaction to the topical gel.

How to Store and Dispose of Lasonil Antidolore

Storage and disposal of Lasonil Antidolore (Ibuprofen lysine salt gel) must strictly follow official regulatory requirements to ensure product stability and environmental safety.

---

Storage Requirements

Requirement	Official Statement
Temperature:	Store below 25°C; do not freeze.
Protection:	Protect from light; keep the tube tightly closed.
Child Safety:	Keep out of the sight and reach of children.

The medicine must be kept in its original container and should not be used past the expiration date (EXP).

Disposal Instructions

Unused or expired Lasonil Antidolore must not be disposed of via wastewater or general household waste. Disposal must be carried out in accordance with local requirements for unused medicinal products to comply with environmental regulations.